Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients

Resmini, Eugenia; Parodi, A. Ferretto; Savarino, Vincenzo; Greco, A; Rebora, Alberto; Minuto, Francesco; Ferone, Diego

doi:10.1210/jc.2006-2509

Cited by 39 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, a recent Swedish study of 162 IBS patients did not support an important role for SBBO, although mildly increased counts of upper small bowel bacteria were observed in IBS patients compared with 26 healthy controls [20]. A variety of other conditions appear to predispose to SBBO, including cirrhosis [21], cystic fibrosis [22], acromegaly [23], celiac sprue [24], and enterocutaneous fistulae [6].…”

Section: Predisposing Factors For Sbbomentioning

confidence: 96%

Small bowel bacterial overgrowth in adults: A potential contributor to intestinal failure

Ziegler

Cole²

2007

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Small bowel bacterial overgrowth (SBBO), in which colon-derived bacteria colonize the upper small bowel, is found in a wide variety of adult diseases associated with intestinal failure and dysfunction, including short bowel syndrome and other conditions following massive bowel resection, dysmotility disorders, and inflammatory bowel disease. SBBO also appears to be relatively common in the elderly, in whom it often goes unrecognized. SBBO is an important cause of malabsorption and thus may contribute to diarrhea and malnutrition. Elevated upper small intestinal aspirate colony counts remain the gold standard diagnostic test; a variety of noninvasive tests that detect elevated levels of breath hydrogen produced by bacterial fermentation of oral carbohydrate loads are also performed for diagnosis. Physicians commonly prescribe a variety of oral antibiotic regimens for documented or presumed SBBO. Additional research is needed to define the epidemiology, optimal diagnostic test(s), and therapeutic regimens for this condition.

show abstract

Section: Predisposing Factors For Sbbomentioning

confidence: 96%

Small bowel bacterial overgrowth in adults: A potential contributor to intestinal failure

Ziegler

Cole²

2007

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…Moreover, there are a very limited number of studies focused on gastrointestinal functional disorders in acromegaly, and it has been shown that active acromegaly may induce impairment of the intestinal motility [16]. Resmini et al revealed prolonged oro-cecal transit time and small intestinal bacterial overgrowth in acromegaly patients [5], and Catnach et al found that gall bladder motor function was severely impaired in untreated acromegaly patients [17]. In another study reporting on gall bladder emptying and small intestinal transit in acromegaly patients, Hussaini et al showed that intestinal transit and gall bladder volume were significantly different between acromegaly patients and controls [18].…”

Section: Discussionmentioning

confidence: 99%

“…intestine and colonic transit time, bacterial overgrowth has been demonstrated in acromegaly patients [5,6]. Additionally, previous studies have shown that somatostatin analogues in the treatment of acromegaly could impair gall bladder emptying, which leads to gallstones [7].…”

Section: Prace Oryginalnementioning

confidence: 99%

Akromegalia może wiązać się z zaburzeniami rozkurczu dolnego zwieracza przełyku (LES)

İlhan

Danalıoğlu

Turgut

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Although prolonged small intestine and colonic transit time has been demonstrated in acromegaly patients, the influence of acromegaly on oesophagus motility and the pathological mechanisms involved are still not clarified. We aimed to investigate manometric measurements to ascertain whether oesophagus motility is affected in active acromegaly patients. Material and methods:The study was performed in an institutional referral centre at a tertiary care hospital. Twenty-three acromegaly patients (mean age 43.2 ± 13.2 years) and 25 sex-and age-matched healthy control subjects (mean age 48.6 ± 7.9 years) were recruited to a case-control study. Oesophageal manometry was performed using MMS (Medical Measurement Systems, Netherlands) Solar GI -Air Charged Intelligent Gastrointestinal Conventional Manometry. Results: In manometric measurements the lower oesophageal sphincter pressure was 18 ± 7 mmHg in acromegaly patients and 15.6 ± 4.4 mm Hg in controls, and there was no significant difference (p = 0.17). The percentage of relaxation was 64.8% and 81.8%, respectively, and it was significantly lower in acromegaly patients than in controls (p < 0.001). Additionally, the duration of relaxation was found to be 4 ± 1.9 seconds and 5 ± 1.7 seconds in patients and controls, respectively (p = 0.049). Conclusions:Our study has demonstrated a significant reduction in the percentage and duration of lower oesophageal sphincter relaxation in oesophagus motility even in acromegaly patients without any gastrointestinal symptoms. Further clinical and pathophysiological studies are required to clarify the underlying mechanisms of gastrointestinal motility disorders in acromegaly. (Endokrynol Pol 2015; 66 (4): 308-312)

show abstract

“…Furthermore, patients were treated with rifaximin and 53% obtained eradication of the bacterial overgrowth at follow-up. Moreover, the analysis of symptoms showed that patients with SIBO presented an increased prevalence of intestinal meteorism and flatulence and after eradication therapy; symptoms disappeared from 60% of the treated patients [41].…”

Section: Sibomentioning

confidence: 99%

Rifaximin pharmacology and clinical implications

Ojetti

Lauritano

Barbaro

et al. 2009

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, with a low gastrointestinal absorption and a good antibacterial activity. The antibacterial action covers Gram-positive and Gram-negative organisms, both aerobes and anaerobes. Its antimicrobial action is based on its property to bind to the beta-subunit of bacterial DNA-dependent RNA polymerase inhibiting, thereby, the bacterial RNA synthesis. Rifaximin contributes to restore gut microflora imbalance, becoming an important therapeutic agent in several organic and functional gastrointestinal diseases such as hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel disease and colonic diverticular disease. This antibiotic has the advantage of low microbial resistance and few systemic adverse events and is safe in all patient populations, including young children.

show abstract

Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients

Cited by 39 publications

References 19 publications

Small bowel bacterial overgrowth in adults: A potential contributor to intestinal failure

Small bowel bacterial overgrowth in adults: A potential contributor to intestinal failure

Akromegalia może wiązać się z zaburzeniami rozkurczu dolnego zwieracza przełyku (LES)

Rifaximin pharmacology and clinical implications

Contact Info

Product

Resources

About